Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076611" target="_blank" >RIV/65269705:_____/22:00076611 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/22:00127579

Výsledek na webu

<a href="https://reader.elsevier.com/reader/sd/pii/S2666621922000710?token=9DD09A6800859A81595192EE67FCE2FEC466E7E295C723E60E619EFC9D5FEF75F4882301653E99326484333501802DF0&originRegion=eu-west-1&originCreation=20230111085226" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S2666621922000710?token=9DD09A6800859A81595192EE67FCE2FEC466E7E295C723E60E619EFC9D5FEF75F4882301653E99326484333501802DF0&originRegion=eu-west-1&originCreation=20230111085226</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cpccr.2022.100207" target="_blank" >10.1016/j.cpccr.2022.100207</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review

Popis výsledku v původním jazyce

The presence of activating somatic mutations in the KRAS and NRAS oncogenes is a negative predictor of treatment with the anti-epidermal growth factor receptor (EGFR) monoclonal antibody in colorectal cancer. The BRAF oncogene also plays an important role in carcinogenesis, and, in colorectal cancer, is associated with an unfavorable prognosis. Mutations in RAS and BRAF are usually considered mutually exclusive. Concomitant mutations present in these oncogenes are rare. However, according to recent analyzes, the incidence of concomitant RAS and BRAF mutations in colorectal cancer may be higher than it is currently expected. In the presented case report of a 44-year-old woman treated for metastatic rectal cancer with concomitant KRAS and BRAF mutations in primary tumor and wild-type KRAS status in metastases, we demonstrated improved survivaloutcome and quality of life after treatment with BRAF inhibitor encorafenib and the anti-EGFR monoclonal antibody cetuximab. Patient Consent Statement: Written informed consent was obtained from the patient&apos;s family for the publication of this report.

Název v anglickém jazyce

Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review

Popis výsledku anglicky

The presence of activating somatic mutations in the KRAS and NRAS oncogenes is a negative predictor of treatment with the anti-epidermal growth factor receptor (EGFR) monoclonal antibody in colorectal cancer. The BRAF oncogene also plays an important role in carcinogenesis, and, in colorectal cancer, is associated with an unfavorable prognosis. Mutations in RAS and BRAF are usually considered mutually exclusive. Concomitant mutations present in these oncogenes are rare. However, according to recent analyzes, the incidence of concomitant RAS and BRAF mutations in colorectal cancer may be higher than it is currently expected. In the presented case report of a 44-year-old woman treated for metastatic rectal cancer with concomitant KRAS and BRAF mutations in primary tumor and wild-type KRAS status in metastases, we demonstrated improved survivaloutcome and quality of life after treatment with BRAF inhibitor encorafenib and the anti-EGFR monoclonal antibody cetuximab. Patient Consent Statement: Written informed consent was obtained from the patient&apos;s family for the publication of this report.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Problems in Cancer: Case Reports

ISSN

2666-6219

e-ISSN

2666-6219

Svazek periodika

2022

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

100207

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85143854833